Apellis Pharmaceuticals News

Express News | Apellis Pharmaceuticals Inc : Raymond James Raises Target Price to $112 From $110

ReutersMay 1 07:33 ET

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

Yahoo FinanceApr 30 10:00 ET

Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho

Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho

Dow JonesApr 29 07:45 ET

Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $52 From $60

ReutersApr 29 06:40 ET

Express News | HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target

BenzingaApr 26 14:22 ET

Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential

TipRanksApr 26 11:45 ET

Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment

Apellis Pharmaceuticals (APLS) said Friday that the review of the marketing authorization application for pegcetacoplan has been reset to day 180, the last phase of the initial assessment by the Europ

MT NewswiresApr 26 10:30 ET

Express News | Apellis Pharmaceuticals Shares Are Trading Higher After the European Medicines Agency Resets Pegcetacoplan Review for Geographic Atrophy to Day 180 of Initial Assessment

BenzingaApr 26 07:22 ET

Express News | European Medicines Agency Has Reset The Review Of Apellis Pharmaceuticals' Intravitreal Pegcetacoplan For Geographic Atrophy To The Last Phase Of The Initial Assessment (Day 180). Apellis Anticipates An Opinion From CHMP No Later Than July 2024

BenzingaApr 26 07:19 ET

Express News | Apellis Pharmaceuticals Inc: Anticipates a Chmp Opinion No Later Than July 2024

ReutersApr 26 07:15 ET

Express News | Apellis Announces Pegcetacoplan Maa Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

ReutersApr 26 07:15 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)

TipRanksApr 26 03:08 ET

Impact of Izervay's Growth on Apellis Pharmaceuticals: Maintaining a Hold Rating Amidst Rising Competition

TipRanksApr 26 02:24 ET

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA's expert groupsApellis anticipates a CHMP opinion no later than July 2024WALTHAM

Apellis PharmaceuticalsApr 26 00:00 ET

Maintaining Market Dominance: Strong Buy Rating on Apellis Pharmaceuticals With a Target Price of $85

TipRanksApr 25 10:15 ET

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter

Apellis PharmaceuticalsApr 23 00:00 ET

Unusual Options Activity: COHR, APLS and Others Attract Market Bets, COHR V/OI Ratio Reaches 294.1

EST Apr 19th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend

moomoo NewsApr 19 16:30 ET

Selling Apellis Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders

Even though Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has fallen by 15% over the past week , insiders who sold US$7.9m worth of stock over the past year have had less luck. Given that the average s

Simply Wall StApr 18 08:41 ET

Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS)

TipRanksApr 18 06:45 ET

Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)

TipRanksApr 18 01:10 ET